These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 38471499)

  • 1. Similar respiratory function including chronic obstructive pulmonary disease between non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease.
    Tsutsumi T; Nakano D; Kawaguchi M; Takahashi H; Kawaguchi T
    Clin Mol Hepatol; 2024 Apr; 30(2):266-268. PubMed ID: 38471499
    [No Abstract]   [Full Text] [Related]  

  • 2. Nonalcoholic Fatty Liver Disease Gets Renamed as Metabolic Dysfunction-Associated Steatotic Liver Disease: Progress But With Challenges.
    Allen AM; Pose E; Reddy KR; Russo MW; Kamath PS
    Gastroenterology; 2024 Feb; 166(2):229-234. PubMed ID: 37949246
    [No Abstract]   [Full Text] [Related]  

  • 3. Waiting for the changes after the adoption of steatotic liver disease.
    Yoon EL; Jun DW
    Clin Mol Hepatol; 2023 Oct; 29(4):844-850. PubMed ID: 37670441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic dysfunction-associated steatotic liver disease: Where does non-alcoholic fatty liver disease in liver transplant recipients fit in this new definition?
    Choudhary NS; Dhampalwar S; Saraf N; Soin AS
    J Hepatol; 2024 Feb; 80(2):e77-e79. PubMed ID: 37717602
    [No Abstract]   [Full Text] [Related]  

  • 5. Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity.
    Kim GA; Moon JH; Kim W
    Clin Mol Hepatol; 2023 Oct; 29(4):831-843. PubMed ID: 37634892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Association Between Liver Histology and Cardiovascular Risk: Time to Introduce Steatotic Liver Disease Screening in High-Risk Patient Groups?
    Boutari C; Athyros VG
    Angiology; 2024 Mar; 75(3):205-207. PubMed ID: 37691291
    [No Abstract]   [Full Text] [Related]  

  • 7. From nonalcoholic steatohepatitis, metabolic dysfunction-associated fatty liver disease, to steatotic liver disease: Updates of nomenclature and impact on clinical trials.
    Yeh ML; Yu ML
    Clin Mol Hepatol; 2023 Oct; 29(4):969-972. PubMed ID: 37718552
    [No Abstract]   [Full Text] [Related]  

  • 8. [Effect of the nomenclature of non-alcoholic fatty liver disease on diagnosis and treatment of fatty liver disease concomitant with other liver diseases].
    Chen L; Jiang LN; Zhao JM
    Zhonghua Gan Zang Bing Za Zhi; 2023 Aug; 31(8):805-809. PubMed ID: 37723061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Severity and Remission of Metabolic Dysfunction-Associated Fatty/Steatotic Liver Disease With Chronic Kidney Disease Occurrence.
    Gao J; Li Y; Zhang Y; Zhan X; Tian X; Li J; Wang R; He Y; Wang A; Wu S
    J Am Heart Assoc; 2024 Mar; 13(5):e032604. PubMed ID: 38390843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Embracing Change: From Nonalcoholic Fatty Liver Disease to Metabolic Dysfunction-Associated Steatotic Liver Disease Under the Steatotic Liver Disease Umbrella.
    Noureddin M; Wei L; Castera L; Tsochatzis EA
    Clin Gastroenterol Hepatol; 2024 Jan; 22(1):9-11. PubMed ID: 37848118
    [No Abstract]   [Full Text] [Related]  

  • 11. Hepatic steatosis and respiratory diseases: a new panorama.
    Botello-Manilla AE; López-Sánchez GN; Chávez-Tapia NC; Uribe M; Nuño-Lámbarri N
    Ann Hepatol; 2021; 24():100320. PubMed ID: 33549735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic dysfunction-associated steatotic liver disease (MASLD) definition is better than MAFLD criteria for lean patients with NAFLD.
    De A; Bhagat N; Mehta M; Taneja S; Duseja A
    J Hepatol; 2024 Feb; 80(2):e61-e62. PubMed ID: 37558135
    [No Abstract]   [Full Text] [Related]  

  • 13. Three-Step Algorithm for Screening High-Risk Group of Metabolic Dysfunction-Associated Steatotic Liver Disease in General Population.
    Oh JH; Jun DW
    Gut Liver; 2024 Mar; 18(2):197-198. PubMed ID: 38481277
    [No Abstract]   [Full Text] [Related]  

  • 14. Therapeutic management of metabolic dysfunction associated steatotic liver disease.
    Zeng J; Fan JG; Francque SM
    United European Gastroenterol J; 2024 Mar; 12(2):177-186. PubMed ID: 38193865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction-associated steatotic liver disease.
    Loomba R; Wong VW
    Aliment Pharmacol Ther; 2024 Jan; 59(2):150-156. PubMed ID: 38153279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic dysfunction associated steatotic liver disease: Current practice, screening guidelines and management in the primary care setting.
    Gupta U; Ruli T; Buttar D; Shoreibah M; Gray M
    Am J Med Sci; 2024 Feb; 367(2):77-88. PubMed ID: 37967750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics.
    Jiang Y; Wu L; Zhu X; Bian H; Gao X; Xia M
    Lipids Health Dis; 2024 Apr; 23(1):95. PubMed ID: 38566209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Discussion from metabolism to fatty liver disease: rethinking the origin of disease and the endpoint of new drugs or metabolic dysfunction-associated steatotic liver disease].
    Xue F; Wei L
    Zhonghua Gan Zang Bing Za Zhi; 2023 Aug; 31(8):785-788. PubMed ID: 37723057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simultaneous Metabolic and Alcohol-associated Fatty Liver Disease (SMAFLD) and Simultaneous Metabolic and Alcohol-associated Steatohepatitis (SMASH).
    Senussi NH; McCarthy DM
    Ann Hepatol; 2021; 24():100526. PubMed ID: 34509272
    [No Abstract]   [Full Text] [Related]  

  • 20. From non-alcoholic fatty liver disease (NAFLD) to steatotic liver disease (SLD): an ongoing journey towards refining the terminology for this prevalent metabolic condition and unmet clinical need.
    Kokkorakis M; Boutari C; Katsiki N; Mantzoros CS
    Metabolism; 2023 Oct; 147():155664. PubMed ID: 37517792
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.